Stay updated on Pembrolizumab/Gemcitabine in ABC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab/Gemcitabine in ABC Clinical Trial page.

Latest updates to the Pembrolizumab/Gemcitabine in ABC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe NIH website transition announcement banner is no longer shown above the ClinicalTrials.gov page, which continues to display a 403 Forbidden error.SummaryDifference1%

- Check20 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0 on the ClinicalTrials.gov page.SummaryDifference0.2%

- Check27 days agoChange DetectedA banner announces an NIH website transition and says that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence.”SummaryDifference1%

- Check34 days agoChange DetectedThe footer revision number changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer’s displayed site revision advances from v3.7.0 to v3.7.1 while the page continues to show a 403 error.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the previous study record content. This blocks access to the NCT03025880 trial details on ClinicalTrials.gov.SummaryDifference21%

Stay in the know with updates to Pembrolizumab/Gemcitabine in ABC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab/Gemcitabine in ABC Clinical Trial page.